Abstract
To evaluate the safety and inimunogenicity of palivizumab, 55 children who received palivizumab in the IMpact-RSV trial received 5 monthly doses of 15 mg/kg palivizumab (Synagis) during the subsequent year. The single child with an antipalivizumab titer of >1/40 had no associated serious adverse events and had expected serum palivizumab trough concentrations. Second year palivizumab prophylaxis was safe and well-tolerated.
Original language | English (US) |
---|---|
Pages (from-to) | 1021-1023 |
Number of pages | 3 |
Journal | Pediatric Infectious Disease Journal |
Volume | 24 |
Issue number | 11 |
DOIs | |
State | Published - Nov 2005 |
Keywords
- Monoclonal antibody
- Palivizumab
- Respiratory syncytial virus
- Synagis
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Microbiology (medical)
- Infectious Diseases